Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of mannan-conjugated house dust mite allergoid immunotherapy for allergic rhinitis/rhinoconjunctivitis
2023-508547-51-00Phase 3Authorised
- Sponsor
- Inmunotek
- Start
- May 2025
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of mannan-conjugated allergoid Dermatophagoides pteronyssinus + Dermatophagoides farinae in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by Inmunotek. Primary endpoint: Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score. Planned start May 2025; status: authorised.
02
Drugs
mannan-conjugated allergoid Dermatophagoides pteronyssinus + Dermatophagoides farinae
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2023-508547-51-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508547-51-00.